ASCO 2012 Breast Cancer Intro

Article

CancerNetwork and the journal ONCOLOGY present exclusive breast cancer coverage from the annual meeting of the American Society of Clinical Oncology (ASCO). Check out the stories below for write-ups of the most important information to come out of this year's event.

CancerNetwork and the journal ONCOLOGY present exclusive breast cancer coverage from the annual meeting of the American Society of Clinical Oncology (ASCO). Check out the stories below for write-ups of the most important information to come out of this year's event.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
2 experts in this video
Related Content
AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

The Role of Artificial Intelligence in Enhancing Precision Medicine for NSCLC

ONCOLOGY Staff
June 24th 2025
Article

AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From The 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

225Ac-LNC1011 targeted α therapy elicited an ORR of 50.0% in patients with PSMA-positive prostate cancer in a phase 1 trial.

Novel Targeted Therapy Shows Promise in PSMA-Positive Prostate Cancer

Tim Cortese
June 24th 2025
Article

225Ac-LNC1011 targeted α therapy elicited an ORR of 50.0% in patients with PSMA-positive prostate cancer in a phase 1 trial.

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
June 19th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.

Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.

Zidesamtinib May Yield Meaningful Outcomes in Advanced ROS1+ NSCLC

Russ Conroy
June 24th 2025
Article

Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.

More than 70% of patients achieve an objective response with isatuximab plus pomalidomide and dexamethasone in the phase 2 EAE115 trial.

Isatuximab Combo Shows Preliminary Activity in Pretreated Multiple Myeloma

Russ Conroy
June 24th 2025
Article

More than 70% of patients achieve an objective response with isatuximab plus pomalidomide and dexamethasone in the phase 2 EAE115 trial.